Legend Biotech Corp Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Legend Biotech Corp (LEGN) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of $2.40 million for the 12-month period ending 2021-12-31, per its 20-F/A filed 2023-02-17.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2023-02-17
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month as first filed |
|---|---|---|
| 2021-12-31 | $2.40M 20-F/A · filed 2023-02-17 | |
| 2020-12-31 | $1.90M 20-F/A · filed 2023-02-17 | $1.91M 20-F · filed 2021-04-02 |
| 2019-12-31 | $1.30M 20-F/A · filed 2023-02-17 | $1.27M 20-F · filed 2021-04-02 |
| 2018-12-31 | $704.00K 20-F · filed 2021-04-02 |